Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Removal of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Conditions: Stage IV Non-small Cell Lung Cancer; Stage IV Melanoma; Triple Negative Breast Cancer; Renal Cell Carcinoma Stage IV Intervention: Combination Product: ImmunicomAIAC Sponsor: Prof. Gal Markel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials